# A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

> **NCT05343637** · PHASE2 · COMPLETED · sponsor: **Respira Therapeutics, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **COMBINATION_PRODUCT:** Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)

## Key facts

- **NCT ID:** NCT05343637
- **Lead sponsor:** Respira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-30
- **Primary completion:** 2020-01-17
- **Final completion:** 2020-01-17
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05343637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05343637, "A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05343637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*